400 Technology Square
About EpizymeEpizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. We systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of our product candidates is directed towards patients with a particular genetically defined cancer. Our approach is part of a broader trend towards personalized therapeutics based on first identifying the underlying cause of a disease affecting specific patient populations, applying rational drug design tools to create a therapeutic to bind with a molecular target in the identified disease pathway and using a companion diagnostic to select the right patients for treatment.
We have built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic. When Epizyme was founded, we recognized that the HMT class of enzymes might contain many potential oncogenes and, therefore, presented the opportunity to discover, develop and commercialize multiple personalized therapeutics.
We have prioritized 20 HMTs as attractive targets for personalized therapeutics based on their oncogenic potential. Our two most advanced therapeutic product programs target the HMTs DOT1L (for the treatment of mixed lineage leukemia, or MLL-r) and EZH2 (for a genetically defined subtype of non-Hodgkin lymphoma). We believe that our ongoing Phase 1 study for EPZ-5676, targeting DOT1L, is the first clinical trial of an HMT inhibitor. We expect to initiate a Phase 1/2 clinical trial of EPZ-6438 targeting EZH2 in 2Q 2013.
We were founded in 2007 and are led by a management team with extensive experience in the pharmaceutical industry. We have entered into therapeutic collaborations with Celgene, Eisai and Glaxo Group Limited (an affiliate of GlaxoSmithKline), or GSK, that have provided us with approximately $120 million in non-equity funding through March 31, 2013. As of March 31, 2012, we had $85 million in cash and cash equivalents.
301 articles about Epizyme
Epizyme today reported second quarter 2022 financial results and provided a business update.
Ipsen announced it is acquiring the company and its cancer drugs, including Tazverik, which were approved for two different indications by the FDA in 2020.
Ipsen and Epizyme announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme.
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R 2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting.
Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwal, Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference.
Epizyme today reported first quarter 2022 financial results and provided a business update.
Epizyme today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET.
Epizyme announced that the Company has granted equity awards to Jerald Korn, the Company’s Chief Operating Officer, with a grant date of April 1, 2022, as equity inducement awards outside of the Company’s 2013 Stock Incentive Plan and material to Mr. Korn’s acceptance of employment with the Company.
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update.
Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, announced its participation in two investor conferences in March.
Epizyme today reported fourth quarter and full year 2021 financial results and provided business and portfolio updates.
Epizyme today announced that management will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update on Tuesday, March 1, 2022 at 8:30 a.m. ET.
Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced the pricing of an underwritten public offering of 56,666,667 shares of its common stock at a price to the public of $1.50 per share, before underwriting discounts.
Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates
Epizyme today provided an update on recent business highlights and its outlook for 2022.
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting
Epizyme, Inc. presented updated safety and activity data from the Phase 1b portion of its Phase 1b/3 confirmatory study evaluating the investigational use of TAZVERIK®, a first-in-class, oral, selective inhibitor of EZH2, in combination with rituximab + lenalidomide in patients with relapsed/refractory follicular lymphoma who have been treated with at least one prior systemic therapy, including patients who are rituximab-refractory and/or POD24.
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting
Epizyme, Inc. shared preclinical data and the Phase 1/1b trial design for EZM0414, the Company’s novel, first-in-class, oral SETD2 inhibitor, an investigational agent being developed for the treatment of adult patients with relapsed or refractory multiple myeloma or with diffuse large B-cell lymphoma.
Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting
Epizyme, Inc. today announced that new data from across its oncology portfolio will be presented at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, taking place from December 11 to 14, 2021 in Atlanta, Georgia.
Epizyme, Inc. today announced two appointments to the Company’s Board of Directors: clinical oncology executive, Roy A. Beveridge, M.D., and international pharmaceutical and financial executive, Carol Stuckley, M.B.A.
Epizyme, Inc. today announced that Grant Bogle, President and Chief Executive Officer of Epizyme, will present at the Jefferies London Healthcare Conference.